SELECT finds semaglutide benefits precede weight loss
- A new SELECT analysis says semaglutide’s heart protection starts fast in adults with obesity, established cardiovascular disease, and no diabetes — before major weight loss. (tctmd.com) - In the original trial, nonfatal heart attack showed the biggest component drop — hazard ratio 0.72 — while the early-look analysis saw benefits by 3 months. (my.clevelandclinic.org) - That matters because it weakens the simple “weight loss explains everything” story and strengthens semaglutide’s case as a cardiovascular drug too. (thelancet.com)
Semaglutide is now doing something more interesting than just helping people lose weight. In the SELECT trial, the drug already showed it could cut major cardiovascular events in people with overweight or obesity, established cardiovascular disease, and no diabetes. The new twist is timing — the benefit seems to show up early, before patients have lost enough weight to explain the whole effect. (tctmd.com) That pushes the conversation away from “this helps the heart because people get lighter” and toward “this may be changing cardiovascular risk through other pathways too.” (my.clevelandclinic.org) ### What was SELECT again? SELECT was the big randomized outcomes trial for semaglutide 2.4 mg — the Wegovy dose — in 17,604 adults age 45 or older with prior cardiovascular disease, a BMI of at least 27, and no history of diabetes. (thelancet.com) Everyone got standard cardiovascular care. Over a mean follow-up of 39.8 months, the semaglutide group had fewer major adverse cardiovascular events than placebo: 6.5% versus 8.0%, for a hazard ratio of 0.80. ### What changed in the new analysis? Investigators went back and asked a more specific question: when does the event reduction begin, and does it line up with weight loss? The answer looks like “earlier than expected.” At the European Congress on Obesity in 2025, researchers said the separation in event curves appeared very early — possibly within weeks — and by 3 months there was already a statistically significant reduction in major adverse cardiovascular events with semaglutide. (nejm.org) ### Why is the timing such a big deal? Because weight loss with semaglutide is real, but it is not immediate in a clinically dramatic sense. Patients are still titrating up dose early in treatment, and meaningful body-weight change usually takes longer to accumulate. (nejm.org) If cardiovascular event curves are already separating before that, weight loss probably is not the whole mechanism. That is the core reason this reanalysis matters. ### Which event moved the most? In the original main trial, nonfatal myocardial infarction stood out. Cleveland Clinic’s trial summary highlighted a hazard ratio of 0.72 for nonfatal MI — about a 28% relative reduction, the largest drop among the major components. The early-window analysis then suggested nonfatal MI was also a major driver of the first-6-month benefit, alongside fewer cardiovascular deaths. (tctmd.com) ### So what else could semaglutide be doing? Probably several things at once. GLP-1 drugs can improve blood sugar dynamics even in people without diabetes, reduce inflammation, lower blood pressure modestly, and affect appetite, endothelial function, and possibly plaque biology. The point is not that weight loss stops mattering — it clearly does — but that semaglutide may start improving the cardiovascular environment before the scale shows the full story. (tctmd.com) That is the simplest way to read these data. ### Is this enough to change practice? For eligible patients, it mostly reinforces a shift already underway. After SELECT, the FDA expanded semaglutide’s indication to include reduction of cardiovascular risk in adults with established cardiovascular disease and overweight or obesity. (my.clevelandclinic.org) The early-benefit analysis adds urgency — basically, it argues against delaying treatment while waiting to “see how lifestyle goes first” in a high-risk patient who already qualifies. ### What is the catch? This early-timing work is a secondary, post hoc analysis, not the primary trial result. That means it is useful and persuasive, but not the same thing as a brand-new dedicated outcomes trial built around early effects. Investigators also noted that some confidence intervals in the secondary analysis were not adjusted for multiplicity, so the exact size of the early benefit should be read carefully. (thelancet.com) ### Bottom line? SELECT first proved semaglutide lowers major cardiovascular events in this population. The reanalysis makes the story sharper — the drug seems to start helping before large weight loss arrives. That does not make weight loss irrelevant. (tctmd.com) But it does mean semaglutide increasingly looks like more than a weight drug that happens to help the heart. It looks like a cardiovascular drug too. (nejm.org) (patientcareonline.com)
